In this interview, Anita Tailor (Merck) discusses biomarker validation and standardization before predicting what the future may hold for biomarker research.
Biomedical research is largely centered on making new discoveries as it relates to human health and disease. The ultimate goal is to understand how human biology works and when and why it goes awry. With a strong foundation on the mechanisms of health and disease, advances in diagnostics and therapeutic interventions can be generated bringing cures to recalcitrant diseases such as cancer and neurodegenerative pathologies.
In this Spotlight interview, Franklin Spriggs (KCAS; KS, USA) explains his interest in biomarkers and introduces the technologies and techniques utilized and offered by KCAS.
Find out more about the current situation for biomarker research in Japan in this Editorial from Bioanalysis.
Read more about the top stories in biomarker developments in this week’s news round-up.
In this podcast, Kevin Ray (MilliporeSigma) discusses the techniques and technologies utilized in drug metabolism studies for biotherapeutics, and what he believes the future holds for the field.
Considerations for developing and validating an LC–MS biomarker assay using the surrogate peptide approach
In this editorial, Timothy Sikorski (GSK; PA, USA), discusses particular considerations for developing and validating LC–MS biomarker assays using the surrogate peptide approach.
Webinar available to view on demand. In this panel discussion, we hear from key experts in the field about their research and expertise, how they overcome key challenges associated with the technologies they work with and what they envision for the future of biomarker research and validation.
Definitive profiling of plasma bile acids as potential biomarkers for human liver diseases using UPLC–HRMS
Find out more about this investigation into a thorough and rapid profiling of bile acids in human plasma in this article from Bioanalysis.
Webinar available to view on demand. Selection and validation of biomarkers can be the difference between the success and failure of a pharmaceutical or biopharmaceutical drug development program.